SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-22-222459
Filing Date
2022-08-17
Accepted
2022-08-16 19:13:43
Documents
11

Document Format Files

Seq Description Document Type Size
1 S-3 d367482ds3.htm S-3 397872
2 EX-1.2 d367482dex12.htm EX-1.2 187410
3 EX-5.1 d367482dex51.htm EX-5.1 34586
4 EX-5.2 d367482dex52.htm EX-5.2 5671
5 EX-23.1 d367482dex231.htm EX-23.1 1696
6 EX-FILING FEES d367482dexfilingfees.htm EX-FILING FEES 32084
7 GRAPHIC g367482dsp69.jpg GRAPHIC 2997
8 GRAPHIC g367482dsp69a.jpg GRAPHIC 3932
9 GRAPHIC g367482g01d04.jpg GRAPHIC 51591
10 GRAPHIC g367482g01d22.jpg GRAPHIC 56080
11 GRAPHIC g367482g01d23.jpg GRAPHIC 52348
  Complete submission text file 0001193125-22-222459.txt   891118
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-266926 | Film No.: 221171691
SIC: 2834 Pharmaceutical Preparations